Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 11/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.45 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 2/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7000181 | 0.92 | PDE9A (0.46) | PDE9APDE1CKMT2ARNASEH1PDE2A | |
| SCHEMBL6995575 | 0.90 | PDE9A (0.46) | PDE9APDE1CKMT2A | |
| SCHEMBL6993272 | 0.87 | PDE9A (0.42) | PDE9APDE1CKMT2ACCNE2CCNE1 | |
| SCHEMBL6990625 | 0.86 | PDE9A (0.45) | PDE9APDE1CPDE5AKMT2APDE2A | |
| SCHEMBL6992823 | 0.81 | PDE9A (0.53) | PDE9APDE1CKMT2APDE2A | |
| SCHEMBL6994822 | 0.80 | PDE9A (0.49) | PDE9APDE1CKMT2APDE2A | |
| SCHEMBL6994147 | 0.79 | PDE9A (0.46) | PDE9APDE1CKMT2APDE2A | |
| SCHEMBL6997618 | 0.78 | PDE9A (0.49) | PDE9APDE1CKMT2APDE2ACCNE2 | |
| SCHEMBL6993084 | 0.78 | PDE9A (0.46) | PDE9APDE1CKMT2APDE2A | |
| SCHEMBL6991004 | 0.77 | PDE9A (0.45) | PDE9APDE1CKMT2APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973774-B1 | 1,5-DIHYDRO-PYRAZOLO 3,4-D]-PYRIMIDINONE DERIVATIVES | BAYER AG (DE) | 2003-01-22 | — | — | EP | disclosed |
| US-6174884-B1 | CARDIOVASCULAR DISORDERS; CEREBROVASCULAR DISEASES; VASCULAR SYSTEM DISORDERS, ESPECIALLY THE PERIPHERAL BLOOD VESSELS; UROGENITAL DISORDERS; HYPOTENSIVE AGENTS; ANTIARRYTHMIA AND -ISCHEMIC AGENTS; PHOSPHODIESTERASE ACTIVITY | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-16 | — | — | US | disclosed |